Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

A. M. Willasch; C. Peters; P. Sedlacek; Dalle J. -H.; V. Kitra-Roussou; A. Yesilipek; J. Wachowiak; A. Lankester; A. Prete; A. A. Hamidieh; M. Ifversen; J. Buechner; G. Krivan; Hamladji R. -M.; C. Diaz-de-Heredia; E. Skorobogatova; G. Michel; Franco Locatelli; A. Bertaina; P. Veys; S. Dupont; R. Or; T. Gungor; O. Aleinikova; S. Sufliarska; M. Sundin; J. Rascon; A. Kaare; D. Nemet; F. Fagioli; T. E. Klingebiel; J. Styczynski; M. Bierings; K. Nagy; M. Abecasis; B. Afanasyev; M. Ansari; K. Vettenranta; A. Alseraihy; A. Chybicka; S. Robinson; Y. Bertrand; A. Kupesiz; A. Ghavamzadeh; A. Campos; H. Pichler; A. Dalissier; M. Labopin; S. Corbacioglu; A. Balduzzi; Galimard J. -E.; P. Bader

doi:10.1038/s41409-020-0854-0

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

A. M. Willasch^*
, C. Peters
, P. Sedlacek
, Dalle J. -H.
, V. Kitra-Roussou
, A. Yesilipek
, J. Wachowiak
, A. Lankester
, A. Prete
, A. A. Hamidieh
, M. Ifversen
, J. Buechner
, G. Krivan
, Hamladji R. -M.
, C. Diaz-de-Heredia
, E. Skorobogatova
, G. Michel
, Franco Locatelli
, A. Bertaina
, P. Veys

S. Dupont, R. Or, T. Gungor, O. Aleinikova, S. Sufliarska, M. Sundin, J. Rascon, A. Kaare, D. Nemet, F. Fagioli, T. E. Klingebiel, J. Styczynski, M. Bierings, K. Nagy, M. Abecasis, B. Afanasyev, M. Ansari, K. Vettenranta, A. Alseraihy, A. Chybicka, S. Robinson, Y. Bertrand, A. Kupesiz, A. Ghavamzadeh, A. Campos, H. Pichler, A. Dalissier, M. Labopin, S. Corbacioglu, A. Balduzzi, Galimard J. -E., P. Bader

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

Lingua originale	Inglese
pagine (da-a)	1540-1551
Numero di pagine	12
Rivista	Bone Marrow Transplantation
Volume	55
Numero di pubblicazione	8
DOI	https://doi.org/10.1038/s41409-020-0854-0
Stato di pubblicazione	Pubblicato - 2020

All Science Journal Classification (ASJC) codes

Ematologia
Trapianto

Keywords

Myeloablative conditioning for allo-HSCT

Accesso al documento

10.1038/s41409-020-0854-0

Altri file e collegamenti

Cita questo

Willasch, A. M., Peters, C., Sedlacek, P., -H., D. J., Kitra-Roussou, V., Yesilipek, A., Wachowiak, J., Lankester, A., Prete, A., Hamidieh, A. A., Ifversen, M., Buechner, J., Krivan, G., -M., H. R., Diaz-de-Heredia, C., Skorobogatova, E., Michel, G., Locatelli, F., Bertaina, A., ... Bader, P. (2020). Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study. Bone Marrow Transplantation, 55(8), 1540-1551. https://doi.org/10.1038/s41409-020-0854-0

@article{24d07d0384304acfabdc91ff21738a2a,

title = "Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study",

abstract = "Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.",

keywords = "Myeloablative conditioning for allo-HSCT, Myeloablative conditioning for allo-HSCT",

author = "Willasch, \{A. M.\} and C. Peters and P. Sedlacek and -H., \{Dalle J.\} and V. Kitra-Roussou and A. Yesilipek and J. Wachowiak and A. Lankester and A. Prete and Hamidieh, \{A. A.\} and M. Ifversen and J. Buechner and G. Krivan and -M., \{Hamladji R.\} and C. Diaz-de-Heredia and E. Skorobogatova and G. Michel and Franco Locatelli and A. Bertaina and P. Veys and S. Dupont and R. Or and T. Gungor and O. Aleinikova and S. Sufliarska and M. Sundin and J. Rascon and A. Kaare and D. Nemet and F. Fagioli and Klingebiel, \{T. E.\} and J. Styczynski and M. Bierings and K. Nagy and M. Abecasis and B. Afanasyev and M. Ansari and K. Vettenranta and A. Alseraihy and A. Chybicka and S. Robinson and Y. Bertrand and A. Kupesiz and A. Ghavamzadeh and A. Campos and H. Pichler and A. Dalissier and M. Labopin and S. Corbacioglu and A. Balduzzi and -E., \{Galimard J.\} and P. Bader",

year = "2020",

doi = "10.1038/s41409-020-0854-0",

language = "English",

volume = "55",

pages = "1540--1551",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Springer Nature",

number = "8",

}

Willasch, AM, Peters, C, Sedlacek, P, -H., DJ, Kitra-Roussou, V, Yesilipek, A, Wachowiak, J, Lankester, A, Prete, A, Hamidieh, AA, Ifversen, M, Buechner, J, Krivan, G, -M., HR, Diaz-de-Heredia, C, Skorobogatova, E, Michel, G, Locatelli, F, Bertaina, A, Veys, P, Dupont, S, Or, R, Gungor, T, Aleinikova, O, Sufliarska, S, Sundin, M, Rascon, J, Kaare, A, Nemet, D, Fagioli, F, Klingebiel, TE, Styczynski, J, Bierings, M, Nagy, K, Abecasis, M, Afanasyev, B, Ansari, M, Vettenranta, K, Alseraihy, A, Chybicka, A, Robinson, S, Bertrand, Y, Kupesiz, A, Ghavamzadeh, A, Campos, A, Pichler, H, Dalissier, A, Labopin, M, Corbacioglu, S, Balduzzi, A, -E., GJ & Bader, P 2020, 'Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study', Bone Marrow Transplantation, vol. 55, n. 8, pagg. 1540-1551. https://doi.org/10.1038/s41409-020-0854-0

TY - JOUR

T1 - Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

AU - Willasch, A. M.

AU - Peters, C.

AU - Sedlacek, P.

AU - -H., Dalle J.

AU - Kitra-Roussou, V.

AU - Yesilipek, A.

AU - Wachowiak, J.

AU - Lankester, A.

AU - Prete, A.

AU - Hamidieh, A. A.

AU - Ifversen, M.

AU - Buechner, J.

AU - Krivan, G.

AU - -M., Hamladji R.

AU - Diaz-de-Heredia, C.

AU - Skorobogatova, E.

AU - Michel, G.

AU - Locatelli, Franco

AU - Bertaina, A.

AU - Veys, P.

AU - Dupont, S.

AU - Or, R.

AU - Gungor, T.

AU - Aleinikova, O.

AU - Sufliarska, S.

AU - Sundin, M.

AU - Rascon, J.

AU - Kaare, A.

AU - Nemet, D.

AU - Fagioli, F.

AU - Klingebiel, T. E.

AU - Styczynski, J.

AU - Bierings, M.

AU - Nagy, K.

AU - Abecasis, M.

AU - Afanasyev, B.

AU - Ansari, M.

AU - Vettenranta, K.

AU - Alseraihy, A.

AU - Chybicka, A.

AU - Robinson, S.

AU - Bertrand, Y.

AU - Kupesiz, A.

AU - Ghavamzadeh, A.

AU - Campos, A.

AU - Pichler, H.

AU - Dalissier, A.

AU - Labopin, M.

AU - Corbacioglu, S.

AU - Balduzzi, A.

AU - -E., Galimard J.

AU - Bader, P.

PY - 2020

Y1 - 2020

N2 - Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

AB - Although most children with acute lymphoblastic leukemia (ALL) receive fractionated total body irradiation (FTBI) as myeloablative conditioning (MAC) for allogeneic hematopoietic stem cell transplantation (allo-HSCT), it is an important matter of debate if chemotherapy can effectively replace FTBI. To compare outcomes after FTBI versus chemotherapy-based conditioning (CC), we performed a retrospective EBMT registry study. Children aged 2–18 years after MAC for first allo-HSCT of bone marrow (BM) or peripheral blood stem cells (PBSC) from matched-related (MRD) or unrelated donors (UD) in first (CR1) or second remission (CR2) between 2000 and 2012 were included. Propensity score weighting was used to control pretreatment imbalances of the observed variables. 3.054 patients were analyzed. CR1 (1.498): median follow-up (FU) after FTBI (1.285) and CC (213) was 6.8 and 6.1 years. Survivals were not significantly different. CR2 (1.556): median FU after FTBI (1.345) and CC (211) was 6.2 years. Outcomes after FTBI were superior as compared with CC with regard to overall survival (OS), leukemia-free survival (LFS), relapse incidence (RI), and nonrelapse mortality (NRM). However, we must emphasize the preliminary character of the results of this retrospective “real-world-practice” study. These findings will be prospectively assessed in the ALL SCTped 2012 FORUM trial.

KW - Myeloablative conditioning for allo-HSCT

UR - https://publicatt.unicatt.it/handle/10807/228167

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85082841595&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85082841595&origin=inward

U2 - 10.1038/s41409-020-0854-0

DO - 10.1038/s41409-020-0854-0

M3 - Article

SN - 0268-3369

VL - 55

SP - 1540

EP - 1551

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 8

ER -

Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?—A multicenter EBMT-PDWP study

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo